30 May, 2011 05:05 PM
Circadian Technologies is now focused on developing VGX-100, a VEGF-C inhibitory monoclonal antibody. Trials will start in late 2011. If safety studies complete as expected, VGX-100 is scheduled to...read more
06 Apr, 2011 02:53 PM
Circadian’s VGX-100 Inhibits Tumour Growth in Models of Lung, Ovarian and Prostate Cancer
Data demonstrates efficacy of VGX-100 with other therapeutic agents in mouse models of lung, ova...read more